About Renovacor
Renovacor is a Healthcare company based in Philadelphia (United States) founded in 2013 by Arthur Feldman, and was acquired by Rocket Pharma in September 2022. BAG3-related gene therapies for cardiovascular and CNS disorders are developed. Renovacor has raised $11 million across 1 funding round from investors including Rocket Pharma, New Leaf Venture Partners and Novartis Venture Fund. Its chief executive, as recorded, is Magdalene Cook. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Drugs and Heart Failure. Its competitors include Kriya Therapeutics, Sana Biotechnology and PureTech Health; 3 of its 3 listed competitors have raised funding.
Company details
Renovacor was founded in 2013 in Philadelphia, United States, within the biotechnology sector. Emphasis is placed on drug development for cardiovascular and central nervous system disorders. BAG3-related gene therapies are pursued, including the candidate molecule REN-001, which remains in preclinical and research stages for cardiomyopathy and CNS indications. Operations center on advancing these therapies toward clinical applications.
- Headquarters Philadelphia, United States
- Founders Arthur Feldman
- Stage Acquired
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website renovacor.com
- Social LinkedIn X
- Acquired by Rocket Pharma (Sep 2022)
- Net Profit-$780.77 K (USD)-150048as on Dec 31, 2020
- EBITDA-$801.96 K (USD)-154123as on Dec 31, 2020
- Total Equity Funding$11M (USD)
in 1 rounds
- Latest Funding Round$11M (USD), Series A
Aug 2019
- InvestorsRocket Pharma
& 5 more
- Acquired byRocket Pharma
(Sep 2022)
Funding Insights of Renovacor
Renovacor has successfully raised a total of $11M through 1 strategic funding round. The most recent funding activity was a Series A round of $11 million completed in August 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $11M
- Total Rounds 1
- Last Round Series A β $11M
- First Round $11M
(Aug 2019)
- Investors Count 5
All 1 funding rounds of Renovacor with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2019 | $11M | Series A | β | Novartis Venture Fund, Broadview Ventures |
6 investors in total: 6 institutional.
Investors in Renovacor
Renovacor has secured backing from 6 investors, including venture fund investors. Prominent investors backing the company include Rocket Pharma, New Leaf Venture Partners and Novartis Venture Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made in innovative life science companies globally. | nvfund.com | Basel, Switzerland | ||
Seed-stage life sciences investments are made in the US. | broadviewventures.org | Boston, United States | ||
| bioadvance.com | ||||
VC firm investing in seed and early stage companies in Italy | innogestcapital.com | Milan, Italy | ||
Stage-agnostic investments in US life sciences are managed. | 2005 | nlvpartners.com | New York, United States | |
Gene-modified cell therapies for rare diseases are developed. | 2015 | rocketpharma.com | New York, United States |
Investor details for Renovacor
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Renovacor
23 people are tracked at Renovacor (8 in leadership, 12 in board & advisors, 3 in team).
| Name | Role | Group |
|---|---|---|
Arthur Feldman | Founder | Leadership |
Magdalene Cook | CEO | Leadership |
Valerie Myers | Senior Director, Preclinical Development | Leadership |
Beth White | Chief Business Officer & SVP, Operations | Leadership |
Matt Killeen | Chief Scientific Officer | Leadership |
Wendy DiCicco | CFO | Leadership |
Jiwen Zhang | Chief Regulatory Officer | Leadership |
Marc Semigran | Chief Medical Officer | Leadership |
Richard Peluso | Scientific Advisor | Board & advisors |
Jonas Grossman | Director | Board & advisors |
Gregory F. Covino | Director | Board & advisors |
Joan Lau | Director | Board & advisors |
Gbola Amusa | Director | Board & advisors |
Lee Sweeney | Scientific Advisor | Board & advisors |
Edward J Benz | Director | Board & advisors |
Dennis McNamara | Scientific Advisor | Board & advisors |
Thomas Needham | Director | Board & advisors |
Douglas Mann | Scientific Advisor | Board & advisors |
Joseph Glorioso III | Scientific Advisor | Board & advisors |
Michael Bristow | Scientific Advisor | Board & advisors |
3 more people are available in the full profile.
Complete people profiles for Renovacor
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Renovacor
3 dated milestones of Renovacor across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Renovacor is founded.
- Funding First funding round of $11.0M.
- Exit Acquired by Rocket Pharma.
Competitors of Renovacor
Renovacor has 3 listed competitors in our database, 3 of them funded. They include Kriya Therapeutics, Sana Biotechnology and PureTech Health.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| sana.com | 2018 | Seattle, United States | $821M | 328 | Genetically engineered cell therapies are developed for multiple disorders. | |
| puretechhealth.com | 2001 | Boston, United States | $107M | 171 | Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases. |
Detailed competitors of Renovacor
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Neurology
3 companies that operate in the same segment as Renovacor (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Renovacor
Complete news archive for Renovacor
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Renovacor
Renovacor was founded in 2013 and raised its 1st funding round 6 years after it was founded.
Renovacor is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.
Magdalene Cook is the CEO of Renovacor, as recorded in our data.
Renovacor is a funded company, having raised a total of $11M across 1 funding round to date. The company's 1st funding round was a Series A of $11M, raised on Aug 2019.
Renovacor was founded in 2013 in Philadelphia, United States, within the biotechnology sector. Emphasis is placed on drug development for cardiovascular and central nervous system disorders. BAG3-related gene therapies are pursued, including the candidate molecule REN-001, which remains in preclinical and research stages for cardiomyopathy and CNS indications. Operations center on advancing these therapies toward clinical applications.
Renovacor's top competitors include Sana Biotechnology, PureTech Health and Kriya Therapeutics.
Renovacor has 6 investors. Key investors include Rocket Pharma, New Leaf Venture Partners, Novartis Venture Fund, Broadview Ventures, and BioAdvance.
Yes. Renovacor was acquired by Rocket Pharma in September 2022.

